Immuneering (IMRX) Consolidated Net Income: 2020-2023
Historic Consolidated Net Income for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.
- Immuneering's Consolidated Net Income fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
- According to the latest figures from Q4 2023, Immuneering's Consolidated Net Income is -$15.5 million, which was down 18.95% from -$13.1 million recorded in Q3 2023.
- Immuneering's Consolidated Net Income's 5-year high stood at -$3.2 million during Q2 2020, with a 5-year trough of -$15.5 million in Q4 2023.
- Moreover, its 3-year median value for Consolidated Net Income was -$12.6 million (2022), whereas its average is -$11.6 million.
- Data for Immuneering's Consolidated Net Income shows a maximum YoY plummeted of 149.56% (in 2021) over the last 5 years.
- Over the past 4 years, Immuneering's Consolidated Net Income (Quarterly) stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then decreased by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
- Its Consolidated Net Income was -$15.5 million in Q4 2023, compared to -$13.1 million in Q3 2023 and -$12.3 million in Q2 2023.